Phase IV O2 Consumption Study in COPD Patients.

NCT02533505 PHASE4 COMPLETED Results posted

A Phase IV study evaluating changes in oxygen consumption and cardiac function in Subjects with Chronic obstructive pulmonary disease (COPD) with resting hyperinflation after administration of Symbicort pMDI 160/4.5 μg.

Details

Lead sponsor	AstraZeneca
Phase	PHASE4
Status	COMPLETED
Enrolment	51
Start date	Tue Aug 25 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri Aug 12 2016 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Chronic Obstructive Pulmonary Disease (COPD)

Interventions

• Budesonide 160 mcg and formoterol fumarate dihydrate 4.5 mcg Inhalation aerosol
• Matching Placebo pMDI 160/4.5 μg

Countries

United States